Quazepam

Introduction Overview

Generic Name

quazepam

Brand Name

Doral

Dosage Form

oral tablet (15 mg)

Drug Class

Benzodiazepines

Pharmacokinetics

Absorption:
Quazepam is rapidly and well absorbed from the gastrointestinal tract following oral administration. Peak plasma concentrations typically occur within 1 to 2 hours after dose intake, supporting its rapid onset of action which is important for treatment of insomnia. The drug's lipophilicity facilitates efficient absorption through the gastric and small intestinal mucosa. Food effect studies have demonstrated no significant impact on the rate or extent of absorption, allowing flexibility with regard to dosing relative to meals.

Distribution:
Once absorbed, quazepam is extensively distributed into body tissues due to its high lipophilicity. It exhibits a large volume of distribution, indicative of substantial tissue binding, particularly in lipid-rich tissues such as the central nervous system. Quazepam is highly protein-bound, mainly to albumin, with an estimated binding of approximately 99%, reducing free drug concentrations in plasma but sustaining a reservoir for prolonged effects. Quazepam and its metabolites readily cross the blood-brain barrier to exert CNS depressant actions relevant to its hypnotic efficacy.

Metabolism:
Quazepam undergoes extensive hepatic metabolism primarily by cytochrome P450 enzymes including CYP3A4 and CYP1A2 isoforms. It is biotransformed into several active and inactive metabolites, among which N-desalkylquazepam (also known as norquazepam) is pharmacologically active with a considerably longer half-life. This long-acting metabolite contributes to the extended hypnotic effect and residual sedation observed in some patients. Phase I metabolism involves hydroxylation and N-desalkylation, followed by phase II conjugation reactions such as glucuronidation which facilitate renal excretion.

Elimination:
The elimination of quazepam and its metabolites is primarily renal. The parent drug and its conjugated metabolites are excreted via urine, with an elimination half-life ranging approximately 39 to 41 hours for quazepam itself, and up to 70 hours for its active metabolite N-desalkylquazepam. This prolonged half-life supports once-daily dosing but also places patients at risk for dose accumulation, especially in the elderly or those with renal impairment. The clearance is altered significantly in hepatic dysfunction due to metabolism reliance, necessitating clinical caution. Fecal excretion constitutes a minor elimination pathway.

Dosage Forms

Available Dosage Forms:
Quazepam is available in the form of oral tablets. The standard marketed formulation is a 15 mg oral tablet designed for once-daily administration at bedtime to treat insomnia. This dosage form ensures ease of administration and accurate dosing.

Dosages for Adults and Adolescents:
The usual adult starting dose for quazepam in the treatment of insomnia is 7.5 mg orally once per day at bedtime, which can be increased to a maintenance dose of 7.5 to 15 mg depending on patient response and tolerability. Dosage escalation should be cautious, ensuring the lowest effective dose is used to minimize adverse effects. Prolonged administration beyond 10 consecutive nights is generally not recommended due to risks of dependence and tolerance. Adolescents under 18 years of age are not approved to use quazepam.

Specific Patient Populations:
In elderly patients or those with compromised hepatic or renal function, dose adjustments may be required given the extended half-life and metabolic clearance alterations. Clinical recommendations stress caution to avoid over-sedation and accumulation. Pregnant women are contraindicated from using quazepam due to the risk of birth defects and neonatal withdrawal syndrome. The drug should also be avoided in patients with respiratory insufficiency or sleep apnea. Breastfeeding is not recommended during quazepam therapy.

Mechanism Of Action

Quazepam is a benzodiazepine class hypnotic agent that exerts its pharmacological effects primarily through positive allosteric modulation of the gamma-aminobutyric acid subtype A (GABAA) receptor complex in the central nervous system. By binding preferentially to the benzodiazepine site located at the interface of the alpha and gamma subunits of GABAA receptors, quazepam enhances the affinity of the receptor for GABA, the chief inhibitory neurotransmitter.

This interaction increases the frequency of chloride channel opening events in response to GABA, resulting in increased chloride ion influx into neurons, leading to hyperpolarization and decreased neuronal excitability. The resultant CNS depression manifests as sedation, anxiolysis, muscle relaxation, and anticonvulsant effects. Quazepam shows relative selectivity for the alpha-1 subunit-containing GABAA receptors, which is thought to underlie its pronounced hypnotic activity with less pronounced anxiolytic or muscle relaxant properties compared to other benzodiazepines.

Biochemically, quazepam's active metabolite, N-desalkylquazepam, sustains the potentiation of GABAergic transmission, contributing to the long duration of action. This prolonged activity is clinically useful in addressing sleep maintenance difficulties seen in insomnia patients. Comparative studies indicate that quazepam's receptor affinity profile is distinct from shorter-acting benzodiazepines, resulting in differential effects on sleep architecture, such as lesser suppression of slow-wave sleep.

Clinical studies have demonstrated quazepam’s efficacy in reducing sleep latency and nocturnal awakenings with minimal next-day impairment at therapeutic doses. The drug's mechanism aligns with broader benzodiazepine pharmacology but offers unique benefits in the treatment of sleep disturbances, supported by pharmacodynamic and pharmacokinetic evidence.

Pharmacological Actions

Positive allosteric modulation of GABAA receptor chloride channels enhancing GABAergic inhibitory neurotransmission
Hypnotic and sedative properties by reduction of central nervous system excitability
Anxiolytic activity contributing to decreased psychomotor agitation associated with insomnia
Muscle relaxant effects through central nervous system depression
Anticonvulsant properties by stabilizing neuronal membranes and preventing seizure propagation
Selective affinity for alpha-1 subunit GABAA receptors resulting in potent hypnotic effect with fewer anxiolytic side effects
Prolonged pharmacological action due to formation of active metabolite N-desalkylquazepam
Minimal suppression of slow-wave sleep, preserving restorative sleep stages
Reduction of sleep latency and nocturnal awakenings improving sleep continuity
Central respiratory depressant potential heightened when combined with opioids or alcohol
Mild cognitive and psychomotor impairment as a dose-related adverse effect
Risk of physical dependence and tolerance with prolonged use
CNS depressant effects that may be additive with other sedatives and anesthetics
Potential to cause amnesia and complex sleep-related behaviors

Therapeutic Or Clinical Uses

Treatment of primary insomnia characterized by difficulty initiating or maintaining sleep
Reduction in sleep latency and nocturnal awakenings in adult patients with sleep disorders
Management of insomnia with early morning awakenings
Short-term use for sleep disorders requiring hypnotic intervention
Potential off-label investigational uses in anxiety-related sleep disturbances
Adjunct therapy in conditions associated with anxiety-induced insomnia
Facilitation of sedative effects during preoperative sedation (occasionally off-label)
Improvement of sleep quality without significant disruption of sleep architecture
Use in patients where maintaining prolonged sleep is clinically desirable
Alternative option among benzodiazepine hypnotics with longer duration of action
Treatment option in patients intolerant to non-benzodiazepine hypnotics
Clinical utility in insomnia associated with depression or psychiatric disorders when managed carefully
Symptomatic relief of insomnia related to transient stressors under medical supervision
Preferred hypnotic in patients requiring once-daily bedtime dosing
Use contraindicated and strictly avoided during pregnancy and breastfeeding

Side Or Adverse Effects

Drowsiness and prolonged sedation, especially in elderly patients
Dizziness leading to increased risk of falls and accidental injury
Headache, which may impact treatment adherence
Fatigue or feeling unusually tired during the day
Dry mouth causing discomfort and potential oral hygiene issues
Gastrointestinal upset including nausea or upset stomach
Rare but severe allergic reactions such as hives, facial swelling, and respiratory distress
Respiratory depression, particularly when combined with opioids or alcohol
Cognitive impairment including confusion, memory disturbances, and impaired judgement
Psychiatric side effects such as agitation, hallucinations, and suicidal ideation
Complex sleep-related behaviors like sleepwalking, sleep-driving, or other activities performed with amnesia
Dependence and withdrawal symptoms upon abrupt discontinuation
Withdrawal symptoms including seizures, muscle tremors, mood changes, and hallucinations
Tolerance development requiring dose escalation for efficacy
Risk of overdose with symptoms like extreme drowsiness, coma, and respiratory failure

Precautions

Use cautiously in elderly patients due to increased sensitivity and risk of falls
Avoid use in patients with chronic respiratory insufficiency or sleep apnea
Do not use in patients with known hypersensitivity to benzodiazepines
Caution in patients with history of drug or alcohol dependence due to abuse potential
Monitor for emergence or worsening of depression, suicidal thoughts or behavior
Avoid abrupt discontinuation after prolonged use to prevent severe withdrawal effects
Pregnancy contraindicated due to teratogenic risk and neonatal withdrawal syndrome
Avoid concomitant use with other CNS depressants without medical supervision
Exercise caution in patients with hepatic or renal impairment due to altered metabolism and clearance
Advise patients not to operate heavy machinery or drive until fully alert
Use effective contraception in women of childbearing age while on therapy
Assess psychiatric history including suicidality or psychosis prior to therapy
Use smallest effective dose for shortest duration to minimize dependence
Regularly evaluate ongoing need for therapy to prevent chronic use
Educate patients and caregivers about potential for complex sleep behaviors

Warnings

Quazepam can cause severe respiratory depression, especially when used with opioids or alcohol
Risk of addiction, misuse, overdose, or death with inappropriate use or high doses
Life-threatening withdrawal symptoms, including seizures, possible upon sudden discontinuation after long-term use
Do not use during pregnancy due to risk of birth defects and neonatal withdrawal syndrome
Patients may experience complex behaviors such as sleepwalking or sleep-driving with amnesia
Use with caution in patients with depression or history of suicidal thoughts
Not approved for use in patients under 18 years of age
Warning about residual next-day sedation impacting activities requiring alertness
Do not stop medication abruptly without medical guidance
Keep medication secured to prevent unauthorized access or diversion
Concurrent use with other sedative drugs increases risk of CNS depression and fatal outcomes
Immediate medical attention required for signs of severe allergic reactions
Potential for overdose with symptoms including coma and respiratory failure
Patients should be monitored for mood or behavioral changes during therapy
Abrupt withdrawal can lead to severe behavioral and neurological symptoms

Contraindication

Hypersensitivity to quazepam or any benzodiazepine derivative
Severe respiratory disorders including chronic obstructive pulmonary disease and sleep apnea
Patients with acute narrow-angle glaucoma
Pregnancy due to teratogenic potential and neonatal risks
Acute intoxication with alcohol, hypnotics, or other CNS depressants
Myasthenia gravis due to muscle relaxant effects
Severe hepatic insufficiency impairing metabolism
Patients with known history of benzodiazepine hypersensitivity reactions
Concurrent use with potent CYP3A4 inhibitors without proper dose adjustment
Previous or current substance abuse without adequate supervision
Children and adolescents under age 18 due to lack of safety and efficacy data
Patients with severe depression accompanied by suicidal tendencies without close monitoring
Do not use in breastfeeding women due to transfer in human milk
Patients with acute narrow-angle glaucoma
Concomitant use with other CNS depressants without medical oversight

Drug Interactions

Additive CNS depressant effects with opioids leading to respiratory depression and death
Enhanced sedation and respiratory suppression with alcohol consumption
Potential pharmacokinetic interactions with CYP3A4 inhibitors increasing quazepam plasma levels
Reduced metabolism with drugs such as ketoconazole or erythromycin raising toxicity risk
Possible interaction with CYP1A2 inhibitors altering drug clearance
Additive effects with other benzodiazepines or sedative-hypnotics causing excessive sedation
Increased risk of cognitive and psychomotor impairment when used with muscle relaxants
Concomitant use with anticonvulsants may alter seizure threshold
Potential interaction with antidepressants affecting CNS activity
May potentiate effect of other CNS-active agents such as antipsychotics
Risk of enhanced side effects when combined with antihistamines possessing sedative properties
Interactions with herbal products like valerian or kava resulting in additive sedation
Possible decreased effectiveness of quazepam when co-administered with enzyme inducers like rifampin
Combination with other respiratory depressants necessitates careful monitoring
Careful dose adjustment required when combined with other drugs influencing hepatic enzymes

Preparations Of The Drug

Oral tablet: 15 mg quazepam per tablet (Brand: Doral)
Tablets designed for oral administration, available as scored tablets to facilitate dose adjustment
Single strength dosage facilitating once-daily bedtime administration
Packaged in blister packs or bottles with child-resistant closures
Formulated for immediate release to enable rapid onset of hypnotic effect
Storage recommendation: Keep at room temperature, protected from moisture and heat
No currently marketed liquid or injectable formulations
No available extended-release or controlled-release formulations
Manufactured according to stringent pharmaceutical standards meeting regulatory approvals
Available in prescription form only, with controlled dispensing due to potential for abuse
Packaging includes clear labeling with dosing instructions and safety warnings
Product monographs and patient information leaflets provided with each dispensing
Storage advice emphasizes securing medication away from unauthorized persons
No combination formulations available; quazepam is marketed as a single-entity preparation
Specialty pharmacy distribution channels for certain patient populations as required